KALIOS.HEALTH

Written by G · Checked · 2 sources

No vendors · No affiliates · Nothing to sell

← Stacks

Pair page — what's published on the two together

Liraglutide with Pramlintide

Studied together in one 2024 mouse study of the antipsychotic olanzapine’s effect on blood sugar, and in passing in a 2023 case report. No trial in people.

Studied together
1 mouse study (2024), 1 case report (2023)
Liraglutide
FDA approved · evidence: Approved drug
Pramlintide
FDA approved · evidence: Controlled trials

Studied Together

Mice given olanzapine (Medak et al., 2024)

  • What was given — Male mice on standard chow got one injection of the antipsychotic olanzapine (5 mg/kg) with vehicle, liraglutide (25 µg/kg, a dose that did not protect on its own), pramlintide (1 µg per mouse) or both, and were followed for 2 hours; 4 to 6 mice per group (open-access full text).
  • What it found — Mice given both had a significantly smaller rise in blood sugar than mice given olanzapine alone, about equal to the two drugs’ separate effects added together. Glucagon fell below detection with the pair, and blood fatty acids fell with the pair but not with either drug alone. The authors: “There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia.”
  • Limits — One 2-hour experiment in male mice, 4 to 6 per group; no weight or long-term data. Funded by the Canadian Institutes of Health Research; the authors declare no competing interests.

A teenager in hospital with heart failure (Srivastava, 2023)

  • What was given — A 15-year-old with severe obesity (400 lb, BMI 71.6) in intensive care for heart failure was started on liraglutide (raised step by step to 3.0 mg a day) and empagliflozin. Pramlintide was also started in hospital but given only briefly: outpatient insurance would not cover it.
  • What it found — He lost 101 lb (25.2%) over 4 months, came off intravenous heart support and went home; his heart’s ejection fraction rose from 12–17% to 39%. After discharge he stayed on liraglutide and empagliflozin.
  • Limits — One patient; pramlintide was brief and given alongside liraglutide, empagliflozin and heart-failure care, so nothing can be credited to the pair. No funding; the author reports consulting fees from Novo Nordisk, Eli Lilly and Rhythm, outside this work.

No trial in people has tested pramlintide with liraglutide, and ClinicalTrials.gov lists none (searched October 3, 2026).

Each Compound's Evidence

What each has shown on its own, from its Kalios card. The full profiles carry the sources.

Liraglutide

Evidence: Approved drug. The daily shot before Ozempic, approved for kids as young as six. Its main trial: 8% weight loss at 56 weeks.

Pramlintide

Evidence: Controlled trials. Approved in 2005 for diabetics on insulin: three shots a day, boxed warning. Not a weight-loss drug.

Legal Status

Current Status — October 2026

Liraglutide: FDA approved. Prescribed by a doctor, made by a manufacturer.

Pramlintide: FDA approved. Prescribed by a doctor, made by a manufacturer.

References

  1. Medak KD, Jeromson S, Bellucci A, Arbeau M, Wright DC. Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine. iScience. 2024;27(1):108628. PMID: 38188526.
  2. Srivastava G. Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death. Obes Pillars. 2023;7:100077. PMID: 37990678.

Last updated: October 3, 2026  |  A literature lookup, not a recommendation to combine anything.